Madrigal Pharmaceuticals Appoints Shannon Kelley as General Counsel

Rhea-AI Summary

Madrigal Pharmaceuticals (NASDAQ:MDGL) has appointed Shannon Kelley as General Counsel, effective August 5, 2024. Kelley, who joined Madrigal in 2024 as Chief Compliance Officer, brings over 20 years of healthcare legal and compliance experience. Previously, she held senior roles at Sanofi and Boston Scientific , and worked in enforcement roles with the U.S. Federal Government.

CEO Bill Sibold praised Kelley's leadership and expertise, highlighting her instrumental role in guiding the company through rapid growth. Kelley expressed enthusiasm about Madrigal's opportunity to deliver groundbreaking therapy for nonalcoholic steatohepatitis (NASH), the leading cause of liver transplantation in women in the U.S. She aims to be a strategic partner in building an industry-leading company with a strong culture of ethics and integrity.

Positive

• Appointment of experienced legal professional Shannon Kelley as General Counsel
• Kelley's extensive 20+ years of healthcare legal and compliance experience
• Potential for strengthened leadership and strategic guidance in a period of rapid growth

Negative

• None.

News Market Reaction – MDGL

-1.12%

1 alert

-1.12% News Effect

On the day this news was published, MDGL declined 1.12%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

CONSHOHOCKEN, Pa., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced the appointment of Shannon Kelley as General Counsel, effective August 5, 2024.

Bill Sibold, Chief Executive Officer of Madrigal, stated, “Shannon is an outstanding leader who brings a wealth of expertise to her new role as General Counsel. She joined the Madrigal team in 2024 as Chief Compliance Officer and played an instrumental role guiding the company through a period of rapid growth. I feel privileged to be working with Shannon and the other members of our leadership team as we build the foundation for Madrigal’s future.”

Ms. Kelley has more than 20 years of diverse healthcare experience as a legal and compliance professional. She joined Madrigal from Sanofi, where she served in roles of increasing responsibility. She was most recently Chief Compliance Officer, North America and Global Specialty Care, responsible for compliance across all therapeutic areas. Prior to Sanofi, Ms. Kelley was Global Compliance and Commercial Legal Counsel for Boston Scientific Corporation. Earlier in her career, she spent ten years in enforcement roles with the U.S. Federal Government. Ms. Kelley was a Trial Attorney for the Department of Justice in Washington, D.C. and an Assistant United States Attorney and Deputy Chief of Litigation for the U.S. Attorney’s Office for the District of Massachusetts focused on healthcare matters. Ms. Kelley earned her J.D. from American University Law School and holds a B.S. degree from Georgetown University in Foreign Service.

Ms. Kelley stated, “At Madrigal, we have a unique opportunity to deliver a groundbreaking therapy to patients living with NASH, the leading cause of liver transplantation in women in the U.S. and the second leading cause for all liver transplantation. Our goal is to build a great company that will be an industry leader for years to come, and I look forward to being a strategic partner to the leadership team and continuing to build a strong culture of ethics and integrity.”

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of NASH. For more information, visit www.madrigalpharma.com.

Investor Contact
Tina Ventura, IR@madrigalpharma.com

Media Contact
Christopher Frates, media@madrigalpharma.com

FAQ

Who is Shannon Kelley and what is her new role at Madrigal Pharmaceuticals (MDGL)?

Shannon Kelley has been appointed as General Counsel of Madrigal Pharmaceuticals (NASDAQ:MDGL), effective August 5, 2024. She previously served as the company's Chief Compliance Officer since joining in 2024.

What is Madrigal Pharmaceuticals (MDGL) focused on developing?

Madrigal Pharmaceuticals (NASDAQ:MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH), which is the leading cause of liver transplantation in women in the U.S.

What is Shannon Kelley's professional background before joining Madrigal Pharmaceuticals (MDGL)?

Before joining Madrigal, Shannon Kelley held senior roles at Sanofi, including Chief Compliance Officer for North America and Global Specialty Care. She also worked at Boston Scientific and spent ten years in enforcement roles with the U.S. Federal Government.

When did Shannon Kelley join Madrigal Pharmaceuticals (MDGL) and in what capacity?

Shannon Kelley joined Madrigal Pharmaceuticals (NASDAQ:MDGL) in 2024 as Chief Compliance Officer before being appointed as General Counsel in August 2024.